Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis

Clinical and Experimental Medicine

Volumn 3, Issue 2, 2003, Pages 65-83

  Fellrath, J M ^a   Du Bois, R M ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cryptogenic fibrosing alveolitis; Idiopathic pulmonary fibrosis; Usual interstitial pneumonia

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA1A INTERFERON; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MEVINOLIN; PENICILLAMINE; PIRFENIDONE; PROSTAGLANDIN E2;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; INTERSTITIAL PNEUMONIA; LABORATORY TEST; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY;

HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; PULMONARY FIBROSIS; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0141918864     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-003-0010-3     Document Type: Review

References (136)

1. King TE, Costabel U, Cordier JF, doPico GA, du Bois RM, Lynch D, Lynch JP III, Myers JL, Panos RJ, Raghu G et al (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 161:646-664
2. Travis WD, King TE, Bateman ED, Lynch DA, Capron F, Center D, Colby TV, Cordier JF, du Bois RM, Galvin J et al (2002) American Thoracic Society/ European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304
3. Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:136-151
4. Gross TJ, Hunninghake GW (2001) Idiopathic pulmonary fibrosis. N Engl J Med 345:517-525
5. du Bois RM, Wells AU (2001) Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J 18:43S-55S
6. Bourke SC, Clague H (2000) Review of cryptogenic fibrosing alveolitis including current treatment guidelines. Postgrad Med J 76:618-624
7. Hamman L, Rich AR (1944) Acute diffuse interstitial fibrosis of the lungs. Bull John Hopkins Hospital 74:177-204
8. Scadding JC, Hinson KFW (1967) Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs):correlation of histology at biopsy with prognosis. Thorax 22:291-304
9. Stack BHR, Choo-Kang YFJ, Heard BE (1972) The prognosis of cryptogenic fibrosing alveolitis. Thorax 27:535-542
10. DeRemee RA, Harrison EG, Andersen HA (1972) The concept of classic interstitial pneumonitis-fibrosis (CIP-F) as a clinico-pathologic syndrome. Chest 61:213-220
11. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY (1976) Idiopathic pulmonary fibrosis: clinical, histological, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann Intern Med 85:769-788
12. Winterbauer RH, Hammar SP, Hallman KO, Hays JE, Pardee NE, Morgan EH, Allen JD, Moores KD, Bush W, Walker JH (1978) Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 65:661-672
13. Turner-Warwick M, Burrows B, Johnson A (1980) Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 35:171-180
14. Liebow AA, Carrington CB (1969) The interstitial pneumonias. In: Simon M, Potchen EJ, LeMay M (eds) Frontiers of pulmonary radiology 1st ed. Grune and Stratton, New York, pp 102-141
15. Katzenstein AL, Myers JL (1998) Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 157:1301-1315
16. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199-203
17. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, du Bois RM (1999) A histological pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 160:899-905
18. Travis WD, Matsui K, Moss J, Ferrans VJ (2000) Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 24:19-33
19. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histological pattern of interstitial pneumonia in patients presenting with the clnical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213-2217
20. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL III, Paine R, Flint A et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19:275-283
21. Katzenstein AL, Zisman DA, Litzky LA, Nguyen BT, Kotloff RM (2002) Usual interstitial pneumonia. Histological study of biopsy and explant specimens. Am J Surg Pathol 26:1567-1577
22. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL III, Flint A, Lynch JP III et al (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722-1727
23. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU (2002) The relationship between individual histological features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 166:173-177
24. Keogh BA, Crystal RG (1982) Alveolitis: the key to interstitial lung disorders. Thorax 37:1-10
25. Strieter RM (2001) Mechanisms of pulmonary fibrosis. Chest 120:S-85S
26. Adamson IYR, Young L, Bowden DH (1988) Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol 130:377-383
27. Sime PJ, Xing Z, Graham FL, Gauldie J (1997) Adenoviral-mediated gene transfer of active TGB-b1 induces prolonged aggressive fibrosis in rat lung. J Clin Invest 100:768-776
28. Schuppan D, Ruehl M, Somasundaram R, Hahn EG (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351-372
29. Peterson MW, Monick M, Hunninghake GW (1987) Prognostic value of eosinophils in pulmonary fibrosis. Chest 92:51-56
30. Turner-Warwick M, Haslam PL (1987) The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 135:26-34
31. Fukuda Y, Basset F, Ferrans VJ, Yamanaka N (1995) Significance of early intraalveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis. Hum Pathol 26:53-61
32. Pardo A, Selman M (2002) Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol 34:1534-1538
33. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A (1995) Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 77:493-504
34. Antoniades HN, Bravo MA, Avila RE, Galanopoulus T, Neville J, Selman M (1990) Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 86:1055-1064
35. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G (1995) Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 152:2163-2169
36. Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH (1991) Increased production and immunohistochemical localization of transforming growth factor beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 5:155-162
37. Nash JR, McLaughlin PJ, Butcher D, Corrin B (1993) Expression of tumour necrosis factor-a in cryptogenic fibrosing alveolitis. Histopathology 22:343-347
38. Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H, Sawai T (2001) Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 17:1220-1227
39. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q (1993) Expression of endothelin-1 in lung of patients with cryptogenic fibrosing alveolitis. Lancet 341:1550-1554
40. Wallace WA, Howie SE (1999) Immunoreactive interleukin-4 and interferon-g expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 187:475-480
41. Majumbar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, du Bois RM, Jeffery PK (1999) Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis. Eur Respir J 14:251-257
42. Wang R, Zagariya A, Ang E, Ibarra-Sunga O, Uhal BD (1999) Fas-induced apoptosis of alveolar epithelial cells requires angiotensin II generation and receptor interaction. Am J Physiol 277:L1245-L1250
43. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, Choudhary G, Oezatalay D, Uhal BD (2000) Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 185:253-259
44. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CRR, Capelozzi VL (2001) Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP). J Clin Pathol 54:132-138
45. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kaneko Y, Hara N (1997) Induction of apoptosis and pulmonary fibrosis in mice response to ligation of Fas antigen. Am J Respir Cell Mol Biol 17:272-278
46. Kuwano K, Hagimoto N, Kawasaki M et al (1999) Essential role of Fas/Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 104:13-19
47. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD (2000) Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 279:L143-L151
48. Uhal BD, Gidea C, Bargout R, Bifero A, Ibarra-Sunga O, Rapp M, Flynn K, Filippatos G (1998) Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol 275:L1013-L1017
49. Kuhn C III, McDonald JA (1991) The roles of the myofibroblast in idiopathic pulmonary fibrosis, ultrastructural and immunohistochemical features of sites of active extracellular matrix Synthesis. Am J Pathol 138:1257-1265
50. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M (1998) Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 275:L1192-L1199
51. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, Hara N (1996) p21 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 154:477-483
52. Phan SH (2002) The myofibroblast in pulmonary fibrosis. Chest 122:286S-289S
53. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M (1995) Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize protaglandin E2 and to express cyclooxygenase-2. J Clin Invest 95:1861-1868
54. Marshall RP, McAnulty RJ, Laurent GL (2000) Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 161:1999-2004
55. Zhang HY, Phan SH (1999) Inhibition of myofibroblast apoptosis by transforming growth factor b1. Am J Respir Cell Mol Biol 21:658-665
56. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M (2002) Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 27:752-758
57. Wang R, Ramos C, Joshi I et al (1999) Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol 277:L1158-L1164
58. Kuwano K, Hagimoto N, Hara N (2001) Molecular mechanisms of pulmonary fibrosis and current treatment. Curr Mol Med 1:551-573
59. Gauldie J (2002) Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 165:1205-1206
60. Bitterman PB, Rennard SI, Keogh BA, Wewers MD, Adelberg S, Crystal RG (1986) Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. N Engl J Med 314:1343-1347
61. Demedts M, Wells AU, Anto JM, Costabel U, Hubbard R, Cullinan P, Slabbynch H, Rizzato G, Poletti V, Verbeken EK et al (2001) Interstitial lung diseases: an epidemiological overview. Eur Respir J 18:2S-16S
62. Thomeer MJ, Costabel U, Rizzato G, Poletti V, Demedts M (2001) Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J 18:114S-118S
63. Scott J, Johnston I, Britton J (1990) What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 301:1015-1017
64. Johnston I, Britton K, Kinnear W, Logan R (1990) Rising mortality from cryptogenic fibrosing alveolitis. BMJ 301:1017-1021
65. Coultas DB, Zumwalt RE, Black WC, Sobonya RE (1994) The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 50:967-972
66. Schweisfurth H (1996) Report by the scientific working group for therapy of lung diseases: German fibrosis register with initial results. Pneumologie 50:899-901
67. Hubbard R, Johnston I, Britton J (1998) Survival in patients with cryptogenic fibrosing alveolitis: a population based cohort study. Chest 113:396-400
68. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D (1999) Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 54:413-419
69. Rizzato G, Bariffi F (1999) Inchiesta epidemiologica sulle interstiziopatic polmonari in Italia: dati e risultati a macchia di leopardo. L'Internista 7:20-24
70. Thomeer M, Demedts M, Vandeurzen K and the VRGT Working Group on Interstitial Lung Diseases (2001) Acta Clin Belg 56:163-172
71. Verleden GM, du Bois RM, Bouros D, Drent M, Millar A, Müller-Quernheim J, Semenzato G, Johnson S, Sourvinos G, Olivieri D et al (2001) Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J 18:17S-29S
72. Baumgartner KB, Samet J, Stidley CA, Colby TV, Waldron J, and the Collaborating Centers (1997) Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:242-248
73. Ryu JH, Colby TV, Hartman TE, Vassallo R (2001) Smoking-related interstitial lung diseases: a concise review. Eur Respir J 17:122-132
74. King TE, Schwarz MI, Brown K, Tooze JA, Tolby TV, Waldron JA, Flint A, Thurlbeck W, Cherniack RM (2001) Idiopathic pulmonary fibrosis. Relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164:1025-1032
75. Nakamura Y, Romberger DJ, Tate L, Ertl RF, Kawamoto M, Adachi Y, Mio T, Sisson JH, Spurzem JR, Rennard SI (1995) Cigarette smoke inhibits lung fibroblast proliferation and chemotaxis. Am J Respir Crit Care Med 151:1497-1503
76. Carnevali S, Nakamura Y, Mio T, Liu X, Takigawa K, Romberger DJ, Spurzem JR, Rennard SI (1998) Cigarette smoke extract inhibits fibroblast-mediated collagen gel contraction. Am J Physiol 274:L591-L598
77. Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, Waldron JA, and the Collaborating Centers (2000) Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 152:307-315
78. Hubbard R (2001) Occupational dust exposure and the aetiology of cryptogenic fibrosing alveolitis. Eur Respir J 18:119S-121S
79. Jacobs RL, Andrews CP, Coalson J (2002) Organic antigen-induced interstitial lung disease: diagnosis and management. Ann Allergy Asthma Immunol 88:30-41
80. Vergnon JM, Vincent M, de The G, Mornex JF, Weynants P, Brune J (1984) Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet II:768-771
81. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA (1995) Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 50:1234-1239
82. Stewart JP, Egan JJ, Ross AJ, Kelly BG, Lok SS, Hasleton PS, Woodcock AA (1999) The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 159:1336-1341
83. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K (2000) Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 55:958-961
84. Kelly BG, Lok SS, Hasleton PS, Egan JJ, Stewart JP (2002) A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 166:510-513
85. Wangoo A, Shaw RJ, Diss TC, Farrell PJ, du Bois RM, Nicholas AG (1997) Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection. Thorax 52:888-891
86. Robinson C, Callow M, Stevenson S, Robinson BWS, Lake RA (2001) Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis. Respir Res 2:119-124
87. Wallace WAH, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE (1994) Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 49:218-224
88. Wallace WAH, Schoffield JA, Lamb D, Howie SEM (1994) Localisation of a pulmonary auto-antigen in cryptogenic fibrosing alveolitis. Thorax 49:1139-1145
89. Wallace WAH, Howie SEM (2001) Upregulation of tenascein and TGFb production in a type II alveolar epithelial cell line by antibody against a pulmonary auto-antigen. J Pathol 195:251-256
90. Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J (1998) Exposure to commonly prescribed drugs and etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 157:743-747
91. Tobin RW, Pope CE II, Pellegrini CA, Emond MJ, Sillery JIM, Raghu G (1998) Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1804-180
92. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA (2001) A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344:573-579
93. Thomas AQ, Lane K, Philipps J III, Prince M, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A, Johnson J et al (2002) Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 165:1322-1328
94. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA (2002) Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest 121:20S-21S
95. Ballard PL, Nogee LM, Beers MF, Ballard RA, Planer BC, Polk L, deMello DE, Moxley MA, Longmore WJ (1995) Partial deficiency of surfactant protein B in infant with chronic lung disease. Pediatrics 96:1046-1052
96. Wilson AG, Hansell DM (2000) Immunologic diseases of the lungs. In: Armstrong P Wilson AG, Dee P, Hansell DM (eds) Imaging of diseases of the chest. Mosby, London, pp 533-635
97. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM (1997) Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 155:1367-1375 (published erratum in Am J Respir Crit Care Med 1997;156:676-677)
98. Xaubet A, Agusti C, Luburich P, Roca J, Monton C, Ayuso MC, Barbera JA, Rodriguez-Roisin R (1998) Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:431-436
99. Nishimura K, Kitaichi M, Izumi T, Nagai S, Kanaoka M, Itoh H (1992) Usual interstitial pneumonia: histological correlation with high-resolution CT. Radiology 182:337-342
100. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP, Toews G (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 169:977-983
101. Wells AU, Hansell DM, Harrioson NK, Lawrence R, Black CM, du Bois RM (1993) Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 6:797-802
102. Mogulkoc N, Brutsche MH, Bishop PW, Murby B, Greaves MS, Horrocks AW, Wilson M, McCullough C, Prescott M, Egan JJ (2001) Pulmonary 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 56:916-923
103. Schwartz DA, Merchant RK, Helmers RA, Gilbert SR, Dayton CS, Hunninghake GW (1991) The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 144:504-506
104. Gunther A, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG et al (1999) Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J 14:565-573
105. McCormack FX, King TE, Bucher BL, Nielsen L, Mason RJ (1995) Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 152:751-759
106. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N (2002) Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165:378-381
107. Kobayashi J, Kitamura S (1995) KL-6: a serum marker for interstitial pneumonia. Chest 108:311-315
108. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S (2000) Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162:1109-1114
109. Fukaya S, Oshima H, Kato K, Komatsu Y, Matsumura H, Ishii K, Miyama H, Nagai T, Tanaka I, Mizutani A et al (2000) KL-6 as novel marker for activities of interstitial pneumonia in connective tissue diseases. Rheumatol Int 19:223-225
110. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K (2000) Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 200:196-201
111. Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, Matsukura A, Kohno S (2003) High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 58:52-57
112. Hunninghake GW, Zimmermann MB, Schwartz DA, King TE, Lynch J, Hegele R, Waldron J, Colby T, Muller N, Lynch D et al (2001) Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164:193-196
113. Swensen S, Aughenbaugh G, Myers J (1997) Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology 205:229-234
114. Tung KT, Wells AU, Rubens MB, Kirk JM, du Bois RM, Hansell DM (1993) Accuracy of the typical computed tomography appearances of fibrosing alveolitis. Thorax 48:334-338
115. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Gowin JD (1999) The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 116:1168-1174
116. Panos RJ, Mortenson RL, Niccoli SA, King TE (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396-404
117. Hubbard R, Venn A, Lewis S, Britton J (2000) Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161:5-8
118. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K (1993) Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103:1808-1812
119. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S (1997) CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol 168:79-83
120. Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM (2000) Acute interstitial pneumonia. Eur Respir J 15:412-418
121. Hartman TE, Primack SL, Kang EY, Swensen SJ, Hansell DM, McGuinness G, Muller NL (1996) Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia: assessment with serial CT. Chest 110:378-382
122. Schwartz DA, Helmers RA, Galvin JR et al (1994) Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 149:450-454
123. Douglas WW, Ryu JH, Schroeder DR (2000) Idiopathic pulmonary fibrosis. Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 161:1172-1178
124. Gay SE, Kazerooni EA, Toews GB, Lynch JP III, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI et al (1998) Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 157:1063-1072
125. Flaherty KR, Toews, GB, Lynch JP III, Kazerooni EA, Gross BH, Strawderman RL, Hariharan, Flint A, Martinez FJ (2001) Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 110:278-282
126. Zisman DA, Lynch JP III, Toews GB, Kazerooni EA, Flint A, Martinez FJ (2000) Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 117:1619-1626
127. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144:291-296
128. Selman M, Carrillo G, Salas J, Padilla RP, Perez-Chavira R, Sansores R, Chapela R (1998) Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 114:507-512
129. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH (1999) A preliminary study of long-term treatment with interferon g-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341:1264-1269
130. Raghu G, Johnson W, Lockhart D, Mageto Y (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 159:1061-1069
131. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB (1999) Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 159:220-227
132. Vassallo R, Matteson E, Thomas CF (2002) Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-a inhibition. Chest 122:1093-1096
133. Niden AH, Koss M, Boylen CT, Azizi N, Chan K (2001) An open label pilot study to determine the potential efficacy of TNFR.FC (Enbrel®, Etanercept) in the treatment of usual interstitial pneumonitis (UIP). Am J Respir Crit Care Med X:A25 (Abstract)
134. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C (1997) Antioxidative and clinical effects of high-dose N-acetyl-cysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 156:1897-1901
135. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ, Greater Manchester Pulmonary Fibrosis Consortium (2001) Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 164:103-108
136. Timmer SJ, Karamzadeh AM, Yung GL, Kriett J, Jamieson SW, Smith CM (2002) Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does PaO2 predict survival? Chest 122:779-784